Company profile
Cytomos Limited is a UK company with status active founded in 2011 based in Scotland.
Financial period: 1 Jan 2025 to 31 Jul 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
MA | Transaction MzQ0MTU5NDIwN2FkaXF6a2N4 | Paper/PDF filed
Published 01 Nov 2024 02:17
RESOLUTIONS | Transaction WURFVkk1OUNhZGlxemtjeA | Paper/PDF filed
Published 01 Nov 2024 01:45
SH01 | Transaction MzQ0MTU4OTk0NmFkaXF6a2N4
Published 31 Oct 2024 11:04
AA | Transaction MzQzNTM4MDc2MmFkaXF6a2N4
Published 12 Sep 2024 08:52
Company registered at Companies House
Cytomos is developing technology to enable non-specialist medical practitioners to complete cell analysis without the need to send samples to laboratories.
Cytomos develops technology to enable non-specialist medical practitioners to complete cell analysis without the need to send samples to laboratories.
Manufacture of electronic measuring, testing etc. equipment, not for industrial process control
Unknown at this time. The company still exists and has 36 shareholders and is still trading though at a loss in the last two years. It continues to receive grant income.
1 Dec 2022 to 31 May 2024
Cytomos is a UK biotechnology SME with a core project team of Lindsay Fraser (CSO, Head of Research/Programme Manager), Gordon Sharp (CTO, Instrument Development), Tom Clayton (Lead System Architect, Firmware/Software Development) and Sevi Giakoumelou (Project and Research Manager, Research Development). The cost of cell therapy for genetic disorders and ...
